focus -WSS

focus

author：leisure time 2025-10-01 00:49:53 - browse：3

From left: Daphne Koller, CEO of Insitro, Vijay Pande of Andreessen Horowitz and scientist Derek Lowe speaking at STAT's Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

Artificial intelligence is a rapidly improving technology. But its progress in drug development faces an increasingly urgent threat: An unending stream of overheated marketing.

To read of AI’s feats in press releases is to learn of a miracle product on the verge of unraveling biology’s most enduring secrets. It can map molecules and accurately predict how they fit together on computer screens. All you need to get to a cure — as they say in infomercials — is act now!

“I am very worried about the hype,” said Daphne Koller, chief executive of the machine learning drug discovery company Insitro, said during STAT’s Breakthrough West Summit in San Francisco last week. “People think (the breakthrough) is going to happen tomorrow.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Bill would allow buprenorphine prescription for addiction via telehealth

hotspot

Wikipedia

WSS

How the political right came to back psychedelics to treat trauma

Why 40% Americans with Parkinson’s don’t see a neurologist

Elizabeth Holmes on track for early release from her 11

Threats against the LGBTQIA+ community intensifying: Department of Homeland Security

Retired US general questions alleged Putin, Prigozhin meeting

Medicare proceeds with plan to claw back hospital funds

entertainment

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

Palantir health business leans on meeting customers’ needs

Trump demands the U.S. pay no more for drugs than other countries … again

Prime Medicine says its gene editing passes test in monkeys

Duchenne breakthrough therapy leaves behind pioneering families

Iowa House, Senate pass 6

Peter Hotez and the public health issue of online harassment

Sarepta Duchenne therapy fails to meet primary endpoint in trial

As demand for Covid shots wanes, Moderna seeks its next success

All of Us, NIH's precision medicine initiative, gets a big boost

entertainment

It's time to get medical device identifiers over the finish line

Lung cancer screening guidelines updated for cigarette smokers

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Beach reads and more: STAT's 2023 summer book list

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Leqembi, other new Alzheimer’s drugs require better biomarkers

hotspot

hotspot

Wikipedia

entertainment